http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113816970-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate | 2021-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113816970-B |
| titleOfInvention | A kind of selective copper ion chelating agent, its preparation method and its application in pulmonary fibrosis |
| abstract | The invention discloses a selective copper ion chelating agent, its preparation method and its application in pulmonary fibrosis. The chelating agent is N-(2-(pyridine-3-yl)thieno[3,2-c ]pyridin-4-yl)acetamide. JYFY‑001 can improve and inhibit the level of pulmonary fibrosis in the body, inhibit the excessive deposition of extracellular matrix in the lung, reduce inflammatory cells, inhibit the proliferation of fibroblasts, improve the blood supply to the lungs to relieve dyspnea, and has a good effect on pulmonary fibrosis. In addition, the drug is not only easy for patients to accept, but also has few side effects and low price. In addition, JYFY‑001 will change the market structure of existing drugs for the treatment of pulmonary fibrosis and become a clinical drug that can be taken for a long time and can effectively inhibit pulmonary fibrosis and improve lung function. |
| priorityDate | 2021-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.